updated
Due to the risk of cardiac safety, the first generation Btk inhibitor ibutinib updated the US manual
Ibutinib is the first generation of irreversible brutton tyrosine kinase (Btk) inhibitors. It has been widely used in the treatment of B-cell lymphoma since it was approved by FDA in november2013. However, the safety of ibutinib has always been concerned. As ibutinib is the first generation of BTK inhibitor, there are still some defects in the development process, including off target effect. In addition to irreversible inhibition of BTK, the drug can also act on a variety of other kinases, including EGFR, ITK, HER2, TEC, etc., which may be related…
